Denali Therapeutics Inc’s recently made public that its President and CEO Watts Ryan J. unloaded Company’s shares for reported $1.11 million on Oct 18 ’24. In the deal valued at $27.69 per share,40,000 shares were sold. As a result of this transaction, Watts Ryan J. now holds 235,807 shares worth roughly $6.38 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, RYAN WATTS bought 40,000 shares, generating $1,096,800 in total proceeds.
Before that, Krognes Steve E. sold 30,000 shares. Denali Therapeutics Inc shares valued at $870,900 were divested by the Director at a price of $29.03 per share. As a result of the transaction, Krognes Steve E. now holds 29,096 shares, worth roughly $0.79 million.
A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who decreased its forecast for the stock in early October from “an Overweight” to “a Neutral”. Citigroup began covering DNLI with “Buy” recommendation on December 13, 2023.
Price Performance Review of DNLI
On Friday, Denali Therapeutics Inc [NASDAQ:DNLI] saw its stock jump 4.20% to $27.05. Over the last five days, the stock has gained 3.44%. Denali Therapeutics Inc shares have risen nearly 26.05% since the year began. Nevertheless, the stocks have risen 42.14% over the past one year. While a 52-week high of $32.13 was reached on 09/18/24, a 52-week low of $14.56 was recorded on 04/25/24. SMA at 50 days reached $27.39, while 200 days put it at $21.82.
Levels Of Support And Resistance For DNLI Stock
The 24-hour chart illustrates a support level at 26.38, which if violated will result in even more drops to 25.72. On the upside, there is a resistance level at 27.60. A further resistance level may holdings at 28.16. The Relative Strength Index (RSI) on the 14-day chart is 49.75, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.24, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 38.78%. Stochastics %K at 42.92% indicates the stock is a holding.
How much short interest is there in Denali Therapeutics Inc?
A steep rise in short interest was recorded in Denali Therapeutics Inc stocks on 2024-10-15, dropping by -1.66 million shares to a total of 7.73 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-13 was 9.4 million shares. There was a decline of -21.52%, which implies that there is a negative sentiment for the stock.
